The themes Danaher is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Los porcentajes de ingresos son estimaciones para six months ended June 26, 2026, no cifras de un informe oficial.
Cytiva bioprocessing products
Filters, resins, liquids, single-use equipment, and services that drugmakers use to develop and manufacture biological medicines.
Pall filtration products
Filters and related equipment that remove contaminants from liquids and gases used in medicine, research, food production, electronics manufacturing, and other industries.
Biacore 8S
A Cytiva instrument that lets researchers test how potential drug molecules interact with their targets.
SCIEX mass spectrometers
Instruments that identify and measure molecules in samples, used in drug research, clinical testing, and food and environmental testing.
Beckman Coulter clinical testing systems
Laboratory instruments, tests, and software that analyze blood and other body samples to help diagnose and monitor health conditions.
Cepheid GeneXpert tests
Systems and tests that detect genetic material from organisms or diseases, including tests used in hospitals and other care settings.
Estados financieros completos →
Danaher owns more than 15 operating companies grouped into biotechnology, life sciences, and diagnostics. Their products help researchers study cells and other biological material, help drugmakers make biological medicines, and help healthcare workers test samples and monitor patients. Many products are used up or replaced regularly, so customers buy supplies as well as instruments and services.
Construido a partir de los propios informes de Danaher Corp. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
232,14 US$-1,3 %cierre 12 nov
Cifras hasta el 25 de septiembre de 2026, del 10-Q presentado el 21 de octubre de 2026
Danaher sells instruments, supplies, and services used in biological research, drug manufacturing, and medical testing.
Grade B+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 40 trimestres del historial de calificaciones de Danaher Corp.. Los otros 38 llegan hasta febrero de 2017.